Prostate cancer Flashcards
Category 1 drugs for non metastatic castrate resistant prostate cancer
apalutamide
darolutamide
enzalutamide
*abiraterone not approved
docetaxel metabolization and contraindication
hepatic, contraindicated with hyperbili
Abiraterone mechanism
Inhibits CYP17 to inhibit androgen biosynthesis
Metabolic interaction with abiraterone
Inhibits CYP17
abiraterone toxicity
*CHF
hypokalemia
HTN
hepatotoxicity
Enzalutamide/apalutamide/darolutamide mechanism
AR receptor blockers preventing translocation of AR to nucleus
Enzalutamide/apalutamide/darolutamide drug interaction
Warfarin and other blood thinners (confirm)
Apalutamide SE’s
hypothyroidism
rash
peripheral edema
arthralgias
ARPI with least cognitive toxicity
darolutamide (low CNS penetration)
approved PARP/ARPI combinations
olaparib or niraparib + abiraterone
talazoparib + enzalutamide
T4 prostate cancer
Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall
T3 prostate cancer
Extraprostatic tumor that is not fixed or does not invade adjacent structures
T3b prostate cancer
Seminal vesicle invasion
T3a prostate cancer
Extraprostatic extension (unilateral or bilateral)
T2 prosate cancer
Tumor is palpable and confined within prostate